Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Advanced Solid Tumors 66Advanced Solid Tumor 56Solid Tumor 42Solid Tumors 40Mesothelioma 38Mesothelioma, Malignant 34Hematopoietic and Lymphatic System Neoplasm 23Solid Tumor, Adult 14Ovarian Neoplasms 13Malignant Solid Neoplasm 13Carcinoma, Non-Small-Cell Lung 13Pancreatic Neoplasms 11Melanoma 11Sarcoma 10Retinoblastoma 9Colorectal Neoplasms 9Stomach Neoplasms 8Lung Neoplasms 8Solid Tumours 7Small Cell Lung Carcinoma 7Advanced Malignant Solid Neoplasm 7Kidney Neoplasms 6Cholangiocarcinoma 6Carcinoma, Renal Cell 6Advanced/Metastatic Solid Tumors 6Advanced or Metastatic Solid Tumors 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Neoplasms 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Cancer × Other solid neoplasm × 90 days × Clear all
NCT06656390 2026-05-22

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

Shanghai Allink Biotherapeutics Co., Ltd.

Phase 1/2 Recruiting
202 enrolled
Other solid neoplasm

Advanced Cancer

NCT02797795 2026-05-13

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers

Neovia Oncology Ltd.

Phase 1 Completed
78 enrolled
Other solid neoplasm

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡